In 2006, we published in the New England Journal of Medicine the ratio test to describe the temporal relationship between these biomarker levels and onset of clinical disease (17), and nearly a decade later, the sFLT1/PlGF ratio test was approved by the FDA and European regulatory authorities for risk stratification in women with suspected preeclampsia during the preterm gestational period (18, 19). This evidence concerns the gene PGF and preeclampsia.